EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of Intergenic and Intragenic MGMT Enhancer Methylation with MGMT Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma

Katharina Pühringer iD, Philipp Czarda iD, Sebastian Iluca, Katja Zappe iD, Serge Weis iD, Sabine Spiegl-Kreinecker, Margit Cichna-Markl iD

International Journal of Molecular Sciences · 04.04.2025 · 26 (7) · 3390

DOI: 10.3390/ijms26073390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.04.2025. Verfasst von Katharina Pühringer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: DNA Methylation, DNA Modification Methylases, Glioblastoma, DNA Repair Enzymes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Access Publishing Fund of the University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The methylation status of the MGMT gene promoter is recognized as a key predictive biomarker for glioblastoma patients, influencing treatment decisions and outcomes. Emerging evidence suggests that enhancer methylation may also play a role in gene regulation and is associated with various clinical parameters, genetic variants, and demographic factors. This study aimed to assess DNA methylation levels in intergenic and intragenic MGMT enhancers to investigate their relationship with MGMT promoter methylation, MGMT protein expression, and clinical and demographic characteristics in glioblastoma. We developed 18 pyrosequencing assays to analyze 54 CpGs, including 34 in intergenic and 20 in intragenic enhancers. The assays were applied to tumor cells derived from 38 glioma patients. Intragenic enhancer CpGs showed significantly higher methylation than intergenic enhancer CpGs. Intragenic enhancer methylation showed a strong negative correlation with MGMT promoter methylation. For several CpGs in intragenic enhancers, an inverse L-shaped relationship between methylation levels and MGMT expression was observed. We identified distinct associations between enhancer methylation and clinical and demographic parameters. Intergenic enhancer methylation was primarily linked to the TERT SNP rs2853669 genotype, Ki-67 expression, age, and sex, whereas intragenic enhancer methylation was associated with MGMT promoter methylation, MGMT expression, overall survival, and progression-free survival. Further studies with larger patient cohorts are needed to validate the clinical relevance of intergenic and intragenic MGMT enhancer methylation in glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationDNA Modification MethylasesGlioblastomaDNA Repair EnzymesPromoter Regions, GeneticTumor Suppressor ProteinsEnhancer Elements, GeneticBrain NeoplasmsHumansMaleFemaleMiddle AgedAdultAgedGene Expression Regulation, NeoplasticCpG IslandsPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

MGMTenhancer methylationglioblastomaintergenic enhancerintragenic enhanceroverall survivalprognostic biomarkerpyrosequencing

Substanzen

DNA Modification MethylasesDNA Repair EnzymesMGMT protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
  • Vienna Doctoral School in Chemistry (DoSChem), University of Vienna, 1090 Vienna, Austria.
  • Division of Neuropathology, Department of Pathology and Molecular Pathology, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.
  • Clinical Research Institute for Neurosciences, Johannes Kepler University, 4020 Linz, Austria.
  • Department of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.

ORCID-Profile: Katharina Pühringer, Philipp Czarda, Katja Zappe, Serge Weis, Margit Cichna-Markl

Förderung

  • Open Access Publishing Fund of the University of Vienna

Zitieren

APA

Pühringer, K., Czarda, P., Iluca, S., Zappe, K., Weis, S., Spiegl-Kreinecker, S., & Cichna-Markl, M. (2025). Association of Intergenic and Intragenic MGMT Enhancer Methylation with MGMT Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma. International Journal of Molecular Sciences, 26(7), 3390. https://doi.org/10.3390/ijms26073390

Vancouver

Pühringer K, Czarda P, Iluca S, Zappe K, Weis S, Spiegl-Kreinecker S, et al. Association of Intergenic and Intragenic MGMT Enhancer Methylation with MGMT Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma. International Journal of Molecular Sciences. 2025;26(7):3390. doi:10.3390/ijms26073390

BibTeX
@article{Phringer2025,
  author = {Pühringer, Katharina and Czarda, Philipp and Iluca, Sebastian and Zappe, Katja and Weis, Serge and Spiegl-Kreinecker, Sabine and Cichna-Markl, Margit},
  title = {Association of Intergenic and Intragenic MGMT Enhancer Methylation with MGMT Promoter Methylation, MGMT Protein Expression and Clinical and Demographic Parameters in Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {3390},
  doi = {10.3390/ijms26073390}
}
Kostenlos starten →